Cargando…

Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis

It is important to develop minimally invasive biomarker platforms to help in the identification and monitoring of patients with Alzheimer’s disease (AD). Assisting in the understanding of biochemical mechanisms as well as identifying potential novel biomarkers and therapeutic targets would be an add...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanas, Jay S., Hocker, James R. S., Vannarath, Christian A., Lerner, Megan R., Blair, Scott G., Lightfoot, Stan A., Hanas, Rushie J., Couch, James R., Hershey, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145311/
https://www.ncbi.nlm.nih.gov/pubmed/33946285
http://dx.doi.org/10.3390/brainsci11050583
_version_ 1783697144337661952
author Hanas, Jay S.
Hocker, James R. S.
Vannarath, Christian A.
Lerner, Megan R.
Blair, Scott G.
Lightfoot, Stan A.
Hanas, Rushie J.
Couch, James R.
Hershey, Linda A.
author_facet Hanas, Jay S.
Hocker, James R. S.
Vannarath, Christian A.
Lerner, Megan R.
Blair, Scott G.
Lightfoot, Stan A.
Hanas, Rushie J.
Couch, James R.
Hershey, Linda A.
author_sort Hanas, Jay S.
collection PubMed
description It is important to develop minimally invasive biomarker platforms to help in the identification and monitoring of patients with Alzheimer’s disease (AD). Assisting in the understanding of biochemical mechanisms as well as identifying potential novel biomarkers and therapeutic targets would be an added benefit of such platforms. This study utilizes a simplified and novel serum profiling platform, using mass spectrometry (MS), to help distinguish AD patient groups (mild and moderate) and controls, as well as to aid in understanding of biochemical phenotypes and possible disease development. A comparison of discriminating sera mass peaks between AD patients and control individuals was performed using leave one [serum sample] out cross validation (LOOCV) combined with a novel peak classification valuation (PCV) procedure. LOOCV/PCV was able to distinguish significant sera mass peak differences between a group of mild AD patients and control individuals with a p value of 10(−13). This value became non-significant (p = 0.09) when the same sera samples were randomly allocated between the two groups and reanalyzed by LOOCV/PCV. This is indicative of physiological group differences in the original true-pathology binary group comparison. Similarities and differences between AD patients and traumatic brain injury (TBI) patients were also discernable using this novel LOOCV/PCV platform. MS/MS peptide analysis was performed on serum mass peaks comparing mild AD patients with control individuals. Bioinformatics analysis suggested that cell pathways/biochemical phenotypes affected in AD include those involving neuronal cell death, vasculature, neurogenesis, and AD/dementia/amyloidosis. Inflammation, autoimmunity, autophagy, and blood–brain barrier pathways also appear to be relevant to AD. An impaired VWF/ADAMTS13 vasculature axis with connections to F8 (factor VIII) and LRP1 and NOTCH1 was indicated and is proposed to be important in AD development.
format Online
Article
Text
id pubmed-8145311
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81453112021-05-26 Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis Hanas, Jay S. Hocker, James R. S. Vannarath, Christian A. Lerner, Megan R. Blair, Scott G. Lightfoot, Stan A. Hanas, Rushie J. Couch, James R. Hershey, Linda A. Brain Sci Article It is important to develop minimally invasive biomarker platforms to help in the identification and monitoring of patients with Alzheimer’s disease (AD). Assisting in the understanding of biochemical mechanisms as well as identifying potential novel biomarkers and therapeutic targets would be an added benefit of such platforms. This study utilizes a simplified and novel serum profiling platform, using mass spectrometry (MS), to help distinguish AD patient groups (mild and moderate) and controls, as well as to aid in understanding of biochemical phenotypes and possible disease development. A comparison of discriminating sera mass peaks between AD patients and control individuals was performed using leave one [serum sample] out cross validation (LOOCV) combined with a novel peak classification valuation (PCV) procedure. LOOCV/PCV was able to distinguish significant sera mass peak differences between a group of mild AD patients and control individuals with a p value of 10(−13). This value became non-significant (p = 0.09) when the same sera samples were randomly allocated between the two groups and reanalyzed by LOOCV/PCV. This is indicative of physiological group differences in the original true-pathology binary group comparison. Similarities and differences between AD patients and traumatic brain injury (TBI) patients were also discernable using this novel LOOCV/PCV platform. MS/MS peptide analysis was performed on serum mass peaks comparing mild AD patients with control individuals. Bioinformatics analysis suggested that cell pathways/biochemical phenotypes affected in AD include those involving neuronal cell death, vasculature, neurogenesis, and AD/dementia/amyloidosis. Inflammation, autoimmunity, autophagy, and blood–brain barrier pathways also appear to be relevant to AD. An impaired VWF/ADAMTS13 vasculature axis with connections to F8 (factor VIII) and LRP1 and NOTCH1 was indicated and is proposed to be important in AD development. MDPI 2021-04-30 /pmc/articles/PMC8145311/ /pubmed/33946285 http://dx.doi.org/10.3390/brainsci11050583 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hanas, Jay S.
Hocker, James R. S.
Vannarath, Christian A.
Lerner, Megan R.
Blair, Scott G.
Lightfoot, Stan A.
Hanas, Rushie J.
Couch, James R.
Hershey, Linda A.
Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title_full Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title_fullStr Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title_full_unstemmed Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title_short Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis
title_sort distinguishing alzheimer’s disease patients and biochemical phenotype analysis using a novel serum profiling platform: potential involvement of the vwf/adamts13 axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145311/
https://www.ncbi.nlm.nih.gov/pubmed/33946285
http://dx.doi.org/10.3390/brainsci11050583
work_keys_str_mv AT hanasjays distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT hockerjamesrs distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT vannarathchristiana distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT lernermeganr distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT blairscottg distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT lightfootstana distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT hanasrushiej distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT couchjamesr distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis
AT hersheylindaa distinguishingalzheimersdiseasepatientsandbiochemicalphenotypeanalysisusinganovelserumprofilingplatformpotentialinvolvementofthevwfadamts13axis